Iovance Biotherapeutics, Inc.

IOVA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-15.8K
Depreciation & Amortization $1.3K
Depreciation —
Amortization —
Stock-Based Compensation $0
Net Cash from Operating Activities $-14.4K
Investing Activities
Capital Expenditures $0
Business Acquisitions —
Net Cash from Investing Activities $0
Financing Activities
Dividends Paid —
Stock Repurchases —
Net Cash from Financing Activities $19.8K
Net Change in Cash $5.4K
Free Cash Flow $-14.4K
← Newer Page 3 of 3 Older →